Sapna Shah, MD
Nephrology · Los Angeles, CANPI 1154664829
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 76.3% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $1,492, more than ten times the $17 reported in 2020.
Across 14 payments — averaging $128.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$1K
- Merck$135
- Calliditas Therapeutics US Inc.$123
- Veloxis Pharmaceuticals, Inc.$108
- Takeda Pharmaceuticals U.S.A., Inc.$22
- Amgen$20
- plus $17 from 1 others
Across 4 payments — averaging $1406.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$6K
What the payments were for
- Travel & lodging$97154%
- Food & beverage$76943%
- Education$633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 4 | $1,376 |
| Merck | 3 | $135 |
| Calliditas Therapeutics US Inc. | 1 | $123 |
| Veloxis Pharmaceuticals, Inc. | 3 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$123
How this compares
$1,802 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 48 | $427,241 |
| LivtencityMaribavir | 16 | $405,393 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $234,454 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $117,197 |
| Valganciclovir Hcl | 84 | $47,516 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $46,917 |
| Cinacalcet Hcl | 118 | $45,906 |
| LokelmaSodium Zirconium Cyclosilicate | 40 | $40,458 |
| Envarsus XrTacrolimus | 16 | $25,152 |
| FarxigaDapagliflozin Propanediol | 29 | $18,298 |
| EliquisApixaban | 12 | $13,942 |
| TrulicityDulaglutide | 13 | $12,332 |
| Tacrolimus | 35 | $5,154 |
| Telmisartan | 127 | $3,976 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $2,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Livtencity | $22 | $832,63564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$2.2M
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.